相似文献
1
Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon.
Trends Parasitol. 2018 Mar;34(3):178-179. doi: 10.1016/j.pt.2017.12.002. Epub 2017 Dec 20.
2
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
Lancet. 2018 Jan 13;391(10116):144-154. doi: 10.1016/S0140-6736(17)32758-7. Epub 2017 Nov 4.
3
Fexinidazole: First Global Approval.
Drugs. 2019 Feb;79(2):215-220. doi: 10.1007/s40265-019-1051-6.
4
Fexinidazole for the treatment of human African trypanosomiasis.
Drugs Today (Barc). 2019 Nov;55(11):705-712. doi: 10.1358/dot.2019.55.11.3068795.
5
Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.
Antimicrob Agents Chemother. 2011 Dec;55(12):5602-8. doi: 10.1128/AAC.00246-11. Epub 2011 Sep 12.
6
Eflornithine for African sleeping sickness.
Lancet. 1999 Jul 17;354(9174):254. doi: 10.1016/S0140-6736(05)66324-6.
7
[Efficacy of Ro 15-0216 against human strains of Trypanosoma gambiense maintained in rodents. A preliminary study].
Bull Soc Pathol Exot Filiales. 1988;81(3 Pt 2):609-15.
8
The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis.
PLoS Negl Trop Dis. 2019 Jun 27;13(6):e0007381. doi: 10.1371/journal.pntd.0007381. eCollection 2019 Jun.
9
Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02515-18. Print 2019 Apr.
10
NECT trial: more than a small victory over sleeping sickness.
Lancet. 2009 Jul 4;374(9683):7-9. doi: 10.1016/S0140-6736(09)61163-6. Epub 2009 Jun 24.
引用本文的文献
1
Pharmacophore Identification and Structure-Activity Relationship Analysis of a Series of Substituted Azaindoles as Inhibitors of .
J Med Chem. 2024 Aug 22;67(16):13985-14006. doi: 10.1021/acs.jmedchem.4c00785. Epub 2024 Aug 13.
2
Insights to Design New Drugs against Human African Trypanosomiasis Targeting Rhodesain using Covalent Docking, Molecular Dynamics Simulations, and MM-PBSA Calculations.
Curr Comput Aided Drug Des. 2025;21(1):67-82. doi: 10.2174/0115734099274797231205055827.
3
Characterization of the Bacterial Profile from Natural and Laboratory Populations.
Insects. 2023 Oct 29;14(11):840. doi: 10.3390/insects14110840.
4
Targeting Cysteine Proteases and their Inhibitors to Combat Trypanosomiasis.
Curr Med Chem. 2024;31(16):2135-2169. doi: 10.2174/0929867330666230619160509.
5
Screening the Pathogen Box to Discover and Characterize New Cruzain and CatL Inhibitors.
Pathogens. 2023 Feb 4;12(2):251. doi: 10.3390/pathogens12020251.
6
Core-Shell DNA-Cholesterol Nanoparticles Exert Lysosomolytic Activity in African Trypanosomes.
Chembiochem. 2022 Oct 19;23(20):e202200410. doi: 10.1002/cbic.202200410. Epub 2022 Sep 20.
7
Current Treatments to Control African Trypanosomiasis and One Health Perspective.
Microorganisms. 2022 Jun 27;10(7):1298. doi: 10.3390/microorganisms10071298.
8
Chemotherapy for second-stage human African trypanosomiasis: drugs in use.
Cochrane Database Syst Rev. 2021 Dec 9;12(12):CD015374. doi: 10.1002/14651858.CD015374.
9
Identification of megacerotonic acid and a quinazoline derivative from Universal Natural Product Database as potential inhibitors of alternative oxidase: molecular docking, molecular dynamic simulation and MM/PBSA analysis.
J Biomol Struct Dyn. 2023 Jan;41(1):45-54. doi: 10.1080/07391102.2021.2003862. Epub 2021 Nov 23.
10
Investigation of thiazolyl-benzothiophenamides as potential agents for African sleeping sickness.
RSC Med Chem. 2020 Sep 23;11(12):1413-1422. doi: 10.1039/d0md00277a. eCollection 2020 Dec 17.
本文引用的文献
1
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
Lancet. 2018 Jan 13;391(10116):144-154. doi: 10.1016/S0140-6736(17)32758-7. Epub 2017 Nov 4.
2
Monitoring the elimination of human African trypanosomiasis: Update to 2014.
PLoS Negl Trop Dis. 2017 May 22;11(5):e0005585. doi: 10.1371/journal.pntd.0005585. eCollection 2017 May.
3
Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.
Clin Pharmacokinet. 2014 Jun;53(6):565-80. doi: 10.1007/s40262-014-0136-3.
4
Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.
Antimicrob Agents Chemother. 2011 Dec;55(12):5602-8. doi: 10.1128/AAC.00246-11. Epub 2011 Sep 12.
5
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.
PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923. doi: 10.1371/journal.pntd.0000923.
6
Eflornithine for the treatment of human African trypanosomiasis.
Parasitol Res. 2003 Jun;90 Supp 1:S49-52. doi: 10.1007/s00436-002-0766-5. Epub 2002 Dec 10.
7
Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.
Trans R Soc Trop Med Hyg. 1995 Jan-Feb;89(1):92-7. doi: 10.1016/0035-9203(95)90673-8.
8
The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice.
Z Parasitenkd. 1983;69(5):577-81. doi: 10.1007/BF00926669.
9
The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica.
Ann Trop Med Parasitol. 1983 Feb;77(1):13-26. doi: 10.1080/00034983.1983.11811668.
Zotero 插件